应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01801 信达生物
休市中 12-19 16:08:06
83.250
+1.700
+2.08%
最高
84.400
最低
80.800
成交量
1,304万
今开
81.900
昨收
81.550
日振幅
4.41%
总市值
1,433亿
流通市值
1,433亿
总股本
17.21亿
成交额
10.85亿
换手率
0.76%
流通股本
17.21亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
医药健康行业周报：蚂蚁阿福带动AI医疗流量 医+药+险全链条赋能
国金证券 · 12-20 00:00
医药健康行业周报：蚂蚁阿福带动AI医疗流量 医+药+险全链条赋能
智通港股解盘 | 海南自贸港封关意义重大 无人驾驶利好密集催化
智通财经 · 12-19 20:58
智通港股解盘 | 海南自贸港封关意义重大 无人驾驶利好密集催化
医药行业 | 2025年医保+商保双目录落地，多元支付体系盘活创新药增量空间
交银国际 · 12-19 17:09
医药行业 | 2025年医保+商保双目录落地，多元支付体系盘活创新药增量空间
信达生物12月19日主力净流入2902.7万元 散户资金抛售
市场透视 · 12-19 16:15
信达生物12月19日主力净流入2902.7万元 散户资金抛售
智通港股早知道 | 国办印发《关于全链条打击涉烟违法活动的意见》 隔夜美股三大股指集体上涨
智通财经 · 12-19 07:27
智通港股早知道 | 国办印发《关于全链条打击涉烟违法活动的意见》 隔夜美股三大股指集体上涨
科学与健康丨登上《自然》！中国降糖减重药有新成果
新华网 · 12-18 17:59
科学与健康丨登上《自然》！中国降糖减重药有新成果
每日卖空追踪 | 信达生物 12月18日卖空量成交104.9万股，卖空比例为10.32%
市场透视 · 12-18 16:30
每日卖空追踪 | 信达生物 12月18日卖空量成交104.9万股，卖空比例为10.32%
谁将是下一个减重蓝海的赢家？
产经头条 · 12-18 16:09
谁将是下一个减重蓝海的赢家？
玛仕度肽两篇研究成果同期在《自然》发表
证券日报 · 12-18
玛仕度肽两篇研究成果同期在《自然》发表
信达生物IBI3033启动I期临床 适应症为哮喘、特应性皮炎
新浪财经 · 12-18
信达生物IBI3033启动I期临床 适应症为哮喘、特应性皮炎
韩国计划将脱发治疗纳入医保；六部门发文加强基层特色科室建设
21世纪经济报道 · 12-18
韩国计划将脱发治疗纳入医保；六部门发文加强基层特色科室建设
诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局
摩熵医药 · 12-18
诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局
12月17日港股药品及生物科技行业沽空数据盘点，信达生物、石药集团、三生制药沽空金额位居行业前三
证券之星APP · 12-17
12月17日港股药品及生物科技行业沽空数据盘点，信达生物、石药集团、三生制药沽空金额位居行业前三
GLP-1赛道或再扩容！信达生物玛仕度肽青少年Ib期临床研究达主要终点 抢滩百亿减重市场
蓝鲸新闻 · 12-16
GLP-1赛道或再扩容！信达生物玛仕度肽青少年Ib期临床研究达主要终点 抢滩百亿减重市场
医保目录“鲶鱼效应” 搅动GLP-1赛道
新快报 · 12-16
医保目录“鲶鱼效应” 搅动GLP-1赛道
每日卖空追踪 | 信达生物 12月15日卖空量成交160.85万股，卖空比例为10.4%
市场透视 · 12-15
每日卖空追踪 | 信达生物 12月15日卖空量成交160.85万股，卖空比例为10.4%
信达生物12月15日主力净流出3053.2万元 散户资金买入
市场透视 · 12-15
信达生物12月15日主力净流出3053.2万元 散户资金买入
千亿市值创新药企俱乐部扩容！百济神州、百利天恒、信达生物等强势崛起
制药网 · 12-15
千亿市值创新药企俱乐部扩容！百济神州、百利天恒、信达生物等强势崛起
国产创新药迎利好密集期！九安医疗产品获FDA批准，一品红斩获近70亿元大单
21世纪经济报道 · 12-15
国产创新药迎利好密集期！九安医疗产品获FDA批准，一品红斩获近70亿元大单
信达生物参与中整协体重与形体管理分会成立，倡导科学减重与健康形体新理念
信达生物 · 12-14
信达生物参与中整协体重与形体管理分会成立，倡导科学减重与健康形体新理念
加载更多
公司概况
公司名称：
信达生物
所属市场：
SEHK
上市日期：
--
主营业务：
信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":83.25,"timestamp":1766131686004,"preClose":81.55,"halted":0,"volume":13042014,"delay":0,"floatShares":1721000000,"shares":1721000000,"eps":-0.06438415376354964,"marketStatus":"休市中","change":1.7,"latestTime":"12-19 16:08:06","open":81.9,"high":84.4,"low":80.8,"amount":1084981389,"amplitude":0.044145,"askPrice":83.25,"askSize":172500,"bidPrice":83.2,"bidSize":47500,"shortable":3,"etf":0,"ttmEps":0.7470448649044036,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":81.55,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":1.1770106193398926,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4059,"impliedVolPercentile":0.065},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2592146391","title":"医药健康行业周报：蚂蚁阿福带动AI医疗流量 医+药+险全链条赋能","url":"https://stock-news.laohu8.com/highlight/detail?id=2592146391","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592146391?lang=zh_cn&edition=full","pubTime":"2025-12-20 00:00","pubTimestamp":1766160000,"startTime":"0","endTime":"0","summary":"投资逻辑本周蚂蚁阿福APP 上市后高流量带动下医疗AI 主题关注度较高。而蚂蚁阿福从AI 工具到AI 朋友全面升级，并上线健康陪伴、健康问答、健康服务三大功能。我们认为蚂蚁阿福是AI 医疗规模化市场与可行商业模式再验证，同时平台流量有望为“医+药+险”全链条赋能。orforglipron 已提交上市申请，获批上市后有望凭依从性优势进一步延长GLP-1 药物使用周期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220193632a6ba7981&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220193632a6ba7981&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828474.EUR","LU2242644610.SGD","01801","LU0455707207.USD","BK1589","LU2097828631.EUR","LU2328871848.SGD","BK1583","LU2097828557.USD","LU1969619763.USD","BK1161","LU2097828714.EUR","LU0502904849.HKD","LU2097828805.USD","HK0000165453.HKD","LU2488822045.USD"],"gpt_icon":0},{"id":"2592162940","title":"智通港股解盘 | 海南自贸港封关意义重大 无人驾驶利好密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2592162940","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592162940?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:58","pubTimestamp":1766149121,"startTime":"0","endTime":"0","summary":"海南自由贸易港昨天正式启动全岛封关，8个对外开放口岸及10个“二线口岸”监管设施全部启用。标志着3万多平方公里的海南岛正式成为海关监管特殊区域，中国对外开放迎来具有里程碑意义的标志性举措。回购的H股股份将作为库存股持有，并在完成回购并披露回购结果公告后三年内完成转让或注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1179","02498","LU1880383366.USD","BK1224","LU1580142542.USD","BK1583","LU1969619763.USD","02039","BK1191","BK1539","02050","BK1163","03908","LU0417516902.SGD","LU1794554557.SGD","06821","LU0455707207.USD","01057","LU1719994722.HKD","01999","02431","BK1500","BK1183","01880","01801","601995","02269","LU0516423091.SGD","LU0348735423.USD","LU2328871848.SGD","03759","BK1564","02533","BK1589","LU0307460666.USD","LU0348766576.USD","LU2039709279.SGD","01316","06160","BK1521","LU0181495838.USD","LU0593848301.USD","LU0819121731.USD","09863","09868","00699","SG9999002463.SGD","01318"],"gpt_icon":1},{"id":"2592117274","title":"医药行业 | 2025年医保+商保双目录落地，多元支付体系盘活创新药增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2592117274","media":"交银国际","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592117274?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:09","pubTimestamp":1766135394,"startTime":"0","endTime":"0","summary":"我们认为，更多新药进入目录，有助提升临床用药水平以及创新药行业整体研发回报率；同时，商保资金的引入将为创新药支付带来重要增量资金，未来商业健康险有望与基本医保错位发展，为多元化支付体系的建立奠定基础。分析师 | 丁政宁、诸葛乐懿本文节选自交银国际已发布研究报告《医药行业-2025年医保+商保双目录落地，多元支付体系盘活创新药增量空间》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219175310a45f8bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219175310a45f8bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0455707207.USD","BK1161","06978","LU1969619763.USD","LU2097828714.EUR","LU2097828805.USD","LU2097828631.EUR","LU2328871848.SGD","LU2488822045.USD","BK1574","BK1589","LU0502904849.HKD","BK1583","LU2097828557.USD","01801","LU2242644610.SGD","HK0000165453.HKD","LU2097828474.EUR"],"gpt_icon":0},{"id":"2592206117","title":"信达生物12月19日主力净流入2902.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592206117","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592206117?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132154,"startTime":"0","endTime":"0","summary":"12月19日, 信达生物股价涨2.08%，报收83.25元，成交金额10.8亿元，换手率0.76%，振幅4.41%，量比1.17。信达生物今日主力资金净流入2902.7万元，上一交易日主力净流出2141.2万元。该股近5个交易日下跌1.76%，主力资金累计净流出3988.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3.3亿元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162114a6b6342f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162114a6b6342f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","LU2097828631.EUR","LU2097828714.EUR","HK0000165453.HKD","LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD","LU2488822045.USD","BK1161","LU0502904849.HKD","01801","LU2097828557.USD","BK1589","LU2097828474.EUR","LU2328871848.SGD"],"gpt_icon":0},{"id":"2592180935","title":"智通港股早知道 | 国办印发《关于全链条打击涉烟违法活动的意见》 隔夜美股三大股指集体上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2592180935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592180935?lang=zh_cn&edition=full","pubTime":"2025-12-19 07:27","pubTimestamp":1766100453,"startTime":"0","endTime":"0","summary":"《意见》要求，聚力打击烟草境外制假走私入境。加强与有关国家执法协作，严厉打击境外假冒中国烟草品牌行为，坚决查处流入、流经我国的非法烟草。《意见》要求，高压严打境内涉烟违法活动。由于该计划及相关附属公司之股东有关变更乃该等程序的结果，本集团并无收取任何现金代价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0611395673.USD","BK1142","LU1105468828.SGD","LU0048580855.USD","BK1148","LU1064130708.USD","BK1610","MPNGY","BK1554","LU1880383366.USD","03393","HMTD.SI","LU0577902371.SGD","LU0348825331.USD","LU0828237510.HKD","BK1583","LU1048588211.SGD","LU1969619763.USD","LU0052750758.USD","LU0082770016.USD","HGmain","BK1209","BK1575","LU0173614495.USD","SG9999002562.SGD","LU0082770016.SGD","LU0051755006.USD","LU0823426308.USD","LU1770034418.SGD","LU0214875030.USD","LU0823038988.USD","LU0819121731.USD","LU0823041008.USD","LU1880383440.USD","LU0211977185.USD","LU0594300179.USD","LU1226287529.USD","LU0287142896.SGD","LU0320764755.SGD","BK1594","LU0370786039.SGD","LU1675838814.USD","LU0823040885.USD","LU0314109678.HKD","LU0359201612.USD","LU2097828474.EUR","LU0345776255.USD","BK1233","LU1960683339.HKD","LU2328871848.SGD","LU0509642566.USD","LU0700851271.USD","LU0588545730.USD","LU0269904917.USD","01801","LU0620787316.HKD","LU0577902298.EUR","LU0865486749.SGD","LU1064131003.USD","LU2097828805.USD","LU0456846285.SGD","SG9999002463.SGD","LU2476274308.USD","METmain","LU0577902538.SGD","BK1604","LU0348816934.USD","BK1521","LU1224709979.USD","LU1008478684.HKD","LU0128522157.USD","LU0417516902.SGD","LU0327786744.USD","SG9999000327.SGD","LU2242644610.SGD","LU2152927971.USD","LU0540923850.HKD","BK1161","LU0143863198.USD","LU0501845795.SGD","LU0449515922.USD","BK1589","LU0117841782.USD","LU0348805143.USD","LU1242518857.USD","LU0164880469.USD","LU0634319403.HKD","CYB","LU0181495838.USD","LU0633140727.USD","CNHmain","LU1770036033.HKD","BK1591","LU1152091168.USD","LU0819123356.HKD","LU0868486357.SGD","LU1188198961.HKD","LU0561508036.HKD","LU1282648689.USD","LU1303224171.USD","BK1615","LU0821914370.USD","LU1868838027.USD","LU1102505929.USD","LU0871576103.HKD","LU1328277881.USD","LU2097828631.EUR","SG9999001689.USD","LU0588545490.SGD","LU0588545904.SGD","LU0072462343.USD","LU0315178854.USD","LU0084288322.USD","LU2097828714.EUR","BK1119","LU2039709279.SGD","LU0577902454.USD","LU0873338254.USD","LU1251922891.USD","LU2045819591.USD","IE0032431581.USD","LU0072913022.USD","LU0348827113.USD","LU0737861699.HKD","LU0261950983.USD","LU1808992512.USD","LU1813983027.USD","IE00B0JY6N72.USD","BK1509","LU0572944931.SGD","LU1481107354.HKD","LU0588546209.SGD","IE00B5MMRT66.SGD","LU0449509016.USD","LU2778985437.USD","LU1048596156.SGD","LU0307460666.USD","LU0708995583.HKD","LU0348814723.USD","BK1179","LU0502904849.HKD","LU0541502299.USD","IE00BPRC5H50.USD","LU0029875118.USD","LU0594300419.USD","LU0605514214.HKD","LU0326948709.USD","LU0589944569.HKD","LU2399975544.HKD","06055","LU0878005551.USD","LU0164939612.USD","LU0348735423.USD","LU0683595622.HKD","BK1539","LU0577902611.USD","LU0650527681.SGD","LU0149721374.USD","HK0000165453.HKD","IE0008369823.USD","LU0164865239.USD","LU0164872284.USD","LU0823426480.USD","LU1868837565.USD","LU1993786604.SGD","BK1618","LU0132412106.USD","LU0165289439.USD","LU0543330483.HKD","LU2226246903.HKD","LU0011963245.USD","LU0455707207.USD","LU0828238088.HKD","LU0231483743.USD","LU0140636845.USD","LU1102505762.USD","LU1868837722.USD","LU2476274720.SGD","LU0499858602.USD","SG9999014674.SGD","LU0541501648.USD","LU2087589342.USD","LU0672654166.SGD","LU1328615791.USD","LU0359202008.SGD","LU1242518931.SGD","BK1580","LU0417516738.SGD","LU0531971595.HKD","LU0047713382.USD","LU1323998911.USD","LU1794554557.SGD","BK1181","LU0345775950.USD","IE0034224299.USD","LU0244354667.USD","LU0048597586.USD","LU0067412154.USD","IE00B29SXG58.USD","LU0593848301.USD","LU2125910500.SGD","LU2488822045.USD","LU0880133367.SGD","IE00B3M56506.USD","LU0251144936.SGD","LU0856984785.SGD","LU1961090484.USD","LU2097828557.USD","LU2148510915.USD","LU0823039010.USD","IE00BF5LJ272.USD","BK1598","LU0633140560.USD","LU1719994722.HKD","LU0431992006.USD","LU1831875114.USD","LU0228659784.USD","LU0348788117.USD","LU2257852520.SGD","LU0196878994.USD","LU0054450605.USD","LU0828237940.HKD","LU1807302812.USD","SG9999002828.SGD","LU0918141705.HKD","LU0039217434.USD","LU0359201885.HKD","IE0008368742.USD","UCmain","LU0106252389.USD","LU0326950275.SGD","LU1734074674.USD","LU0463099449.HKD","LU1152091754.HKD","LU0054237671.USD","SG9999000459.SGD","LU0797268264.HKD","LU0320764599.SGD","SG9999001903.USD","LU0043850808.USD","LU0049853897.USD","LU1023057109.AUD","LU0210526637.USD","LU0979878070.USD","LU0499858438.USD","LU0918141887.USD","LU0143863784.USD","LU1720050803.USD","LU0456827905.SGD","IE00B031HY20.USD","IE00B543WZ88.USD","LU1688375341.USD"],"gpt_icon":0},{"id":"2592418332","title":"科学与健康丨登上《自然》！中国降糖减重药有新成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2592418332","media":"新华网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592418332?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:59","pubTimestamp":1766051953,"startTime":"0","endTime":"0","summary":"中国降糖减重药有新成果新华社记者徐鹏航、陈席元基于中国国产创新药，由中国科研人员牵头、针对糖尿病治疗的降糖减重研究取得亮眼成果，12月18日登上国际知名学术期刊《自然》。参与研究的国内代谢与内分泌领域多位专家表示，此次临床研究成果正是基于中国患者，研究结论能够真实反映中国患者的疾病特征和治疗需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218180213a45b0482&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218180213a45b0482&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","LU0502904849.HKD","BK1574","LU0455707207.USD","LU2242644610.SGD","06978","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","01801","BK1583","BK1589","HK0000165453.HKD","BK1161","LU2097828631.EUR","LU2097828474.EUR","LU2097828805.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2592183378","title":"每日卖空追踪 | 信达生物 12月18日卖空量成交104.9万股，卖空比例为10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592183378","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592183378?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:30","pubTimestamp":1766046623,"startTime":"0","endTime":"0","summary":"信达生物北京时间12月18日，涨0.99%，卖空量成交104.9万股，较上一交易日减少48.77%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163321a45aa19e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218163321a45aa19e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1161","LU2242644610.SGD","HK0000165453.HKD","LU1969619763.USD","BK1583","LU0455707207.USD","LU2097828474.EUR","LU2097828557.USD","LU0502904849.HKD","LU2097828805.USD","LU2328871848.SGD","LU2097828714.EUR","LU2097828631.EUR","01801","LU2488822045.USD"],"gpt_icon":0},{"id":"2592833021","title":"谁将是下一个减重蓝海的赢家？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592833021","media":"产经头条","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592833021?lang=zh_cn&edition=full","pubTime":"2025-12-18 16:09","pubTimestamp":1766045345,"startTime":"0","endTime":"0","summary":"数据显示，肥胖儿童中有近80%存在父母至少一方超重或肥胖的情况。青少年减重作为潜在的蓝海市场，实则有极高的准入壁垒。这是中国生物科技为全球减重降糖领域提供的中国方案。因为在这片蓝海，不是对一个市场份额的抢占，而是对中国家庭、中国青少年的健康承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162337a6b1a62f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218162337a6b1a62f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","HK0000165453.HKD","LU2097828805.USD","LU2328871848.SGD","BK1161","LU1969619763.USD","LU2488822045.USD","LU2097828474.EUR","LU0502904849.HKD","LU2097828557.USD","BK1583","LU2242644610.SGD","LU2097828714.EUR","LU0455707207.USD","01801","BK1589"],"gpt_icon":0},{"id":"2592924411","title":"玛仕度肽两篇研究成果同期在《自然》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924411","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592924411?lang=zh_cn&edition=full","pubTime":"2025-12-18 13:37","pubTimestamp":1766036275,"startTime":"0","endTime":"0","summary":"玛仕度肽两篇研究成果同期在《自然》发表","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595306877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2242644610.SGD","LU2097828474.EUR","LU0455707207.USD","BK1589","LU2328871848.SGD","BK1161","LU2097828557.USD","BK1583","LU2097828631.EUR","01801","LU1969619763.USD","LU2097828714.EUR","LU2097828805.USD","LU2488822045.USD","HK0000165453.HKD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2592973606","title":"信达生物IBI3033启动I期临床 适应症为哮喘、特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973606","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973606?lang=zh_cn&edition=full","pubTime":"2025-12-18 12:03","pubTimestamp":1766030580,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的一项评估IBI3033在健康受试者中安全性、耐受性及药代动力学的随机、双盲、安慰剂对照、单次给药剂量递增研究已启动。IBI3033为生物制品，适应症为哮喘、特应性皮炎。哮喘是气道慢性炎症疾病，症状有喘息、气促等，通过肺功能等检查诊断。特应性皮炎与遗传等有关，表现为皮肤瘙痒、红斑等，主要依据症状诊断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218130505a6b0ed62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218130505a6b0ed62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","LU2097828805.USD","BK1589","LU0502904849.HKD","LU2328871848.SGD","LU1969619763.USD","LU2097828557.USD","LU2488822045.USD","BK1161","01801","LU2097828474.EUR","LU2097828631.EUR","LU0455707207.USD","LU2242644610.SGD","LU2097828714.EUR","BK1583"],"gpt_icon":1},{"id":"2592497396","title":"韩国计划将脱发治疗纳入医保；六部门发文加强基层特色科室建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2592497396","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592497396?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:19","pubTimestamp":1766027955,"startTime":"0","endTime":"0","summary":"鼓励其他基层医疗卫生机构结合实际建设特色科室。与预防性HPV疫苗不同，其专门针对已感染HPV并出现相关病变的患者。与传统的手术切除相比，该疗法可使女性患者保留完整的宫颈。韩国计划将脱发治疗纳入医保韩国总统李在明12月16日在听取韩国保健福祉部等部门工作汇报时下达指示，要求保健福祉部推进将脱发治疗纳入医疗保险的工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218112205a4598153&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218112205a4598153&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2328871848.SGD","LU2488822045.USD","LU0502904849.HKD","HK0000165453.HKD","LU1969619763.USD","LU2242644610.SGD","LU2097828714.EUR","BK1161","LU2097828557.USD","LU0455707207.USD","LU2097828631.EUR","BK1583","01801","BK1589","LU2097828474.EUR"],"gpt_icon":0},{"id":"2592973957","title":"诺和诺德：Wegovy®狂飙与9000人裁员背后的GLP-1赛道变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973957","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973957?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:07","pubTimestamp":1766027230,"startTime":"0","endTime":"0","summary":"2025年第三季度，诺和诺德的核心产品Wegovy销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回2170亿美元以上。诺和诺德在美国的“高增长”依赖的是Wegovy的爆发式放量，而非整体产品线扩张。诺和诺德虽凭Wegovy实现高增长，却因技术代差、市场饱和与研发滞后被迫战略收。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218110738a4597356&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2488822045.USD","01801","HK0000165453.HKD","01276","LU1969619763.USD","BK1583","BK1161","LU0455707207.USD","03933","BK1589","02196","LU2097828631.EUR","LU2097828557.USD","LU0502904849.HKD","LU2328871848.SGD","LU2097828474.EUR","LU2097828714.EUR","LU2242644610.SGD"],"gpt_icon":0},{"id":"2592910426","title":"12月17日港股药品及生物科技行业沽空数据盘点，信达生物、石药集团、三生制药沽空金额位居行业前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2592910426","media":"证券之星APP","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592910426?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:06","pubTimestamp":1765965972,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日港交所披露数据显示，当日港股药品及生物科技行业的159只个股中有83只被沽空，总沽空股数为1.01亿股，总沽空金额为15.15亿元（港元），而当日药品及生物科技行业的总成交金额为89.09亿元（港元），沽空比例为17.0%。从沽空金额来看，信达生物、石药集团、三生制药沽空金额位居行业前三，分别为1.65亿港元、1.52亿港元、1.2亿港元。沽空与卖空含义相同，即在并不持有股票的前提下，通过借入股票获得筹码进而卖出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217181708a45681d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217181708a45681d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0314109678.HKD","BK1161","BK1589","HK0000165453.HKD","LU0140636845.USD","LU2097828805.USD","LU1960683339.HKD","BK1515","LU1969619763.USD","LU2097828714.EUR","BK1583","LU1226288253.USD","LU1813983027.USD","BK1593","IE00BZ08YR35.GBP","LU1328277881.USD","LU0501845795.SGD","LU1226287792.SGD","LU1226288170.HKD","LU1993786604.SGD","LU1807302812.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU2097828474.EUR","LU2328871848.SGD","IE0008368742.USD","LU1152091754.HKD","IE0008369823.USD","SG9999004220.SGD","LU1226287529.USD","LU0326950275.SGD","LU0455707207.USD","LU2039709279.SGD","LU0315179316.USD","LU1008478684.HKD","IE00B031HY20.USD","LU2097828631.EUR","LU0502904849.HKD","LU0067412154.USD","LU2242644610.SGD","01801","01093","IE00B5MMRT66.SGD","LU1152091168.USD","LU0072913022.USD","01530","BK1521","BK1191"],"gpt_icon":0},{"id":"2591078605","title":"GLP-1赛道或再扩容！信达生物玛仕度肽青少年Ib期临床研究达主要终点 抢滩百亿减重市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2591078605","media":"蓝鲸新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591078605?lang=zh_cn&edition=full","pubTime":"2025-12-16 14:54","pubTimestamp":1765868082,"startTime":"0","endTime":"0","summary":"【GLP-1赛道或再扩容！信达生物玛仕度肽青少年Ib期临床研究达主要终点 抢滩百亿减重市场】国内尚无任何儿童、青少年减重药物获批。信达生物GCG／GLP-1双受体激动剂玛仕度肽开始拓展青少年肥胖人群适应症。近日，信达生物公告，玛仕度肽在中国青少年肥胖人群中的Ib期临床研究达到主要终点。信达方面表示，基于该Ib期积极的安全性和疗效结果，信达生物计划于近期启动一项在青少年肥胖或超重参与者中的注册临床III期研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592954568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","LU0455707207.USD","LU2097828805.USD","LU0502904849.HKD","LU2097828631.EUR","BK1589","LU1969619763.USD","BK4590","LU2242644610.SGD","LU2488822045.USD","LU2328871848.SGD","LU2097828714.EUR","GLP","LU2097828474.EUR","HK0000165453.HKD","BK4144","LU2097828557.USD","01801"],"gpt_icon":0},{"id":"2591673763","title":"医保目录“鲶鱼效应” 搅动GLP-1赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2591673763","media":"新快报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591673763?lang=zh_cn&edition=full","pubTime":"2025-12-16 08:23","pubTimestamp":1765844580,"startTime":"0","endTime":"0","summary":"近日，国家医保局公布的新版医保目录中，礼来的替尔泊肽与国产新秀银诺医药的依苏帕格鲁肽α双双被纳入医保，适应证均为2型糖尿病治疗。作为2025年1月刚获批的国产长效GLP-1，其医保谈判成功被视为“国产药的重要突破”。信达生物方面已公开表示，玛仕度肽是公司重点产品，未来将积极争取纳入医保目录。中国GLP-1肥胖或超重药物市场预期将从2024年的人民币4亿元增加至2028年的95亿元，年复合增长率为123.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216082332a6a6f41b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216082332a6a6f41b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1589","LU2097828631.EUR","LU2097828474.EUR","01801","LU2488822045.USD","LU0502904849.HKD","LU2097828557.USD","LU0455707207.USD","HK0000165453.HKD","LU2242644610.SGD","BK1583","LU1969619763.USD","LU2097828714.EUR","LU2328871848.SGD","LU2097828805.USD"],"gpt_icon":0},{"id":"2591197536","title":"每日卖空追踪 | 信达生物 12月15日卖空量成交160.85万股，卖空比例为10.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591197536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591197536?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787424,"startTime":"0","endTime":"0","summary":"信达生物北京时间12月15日，跌4.05%，卖空量成交160.85万股，较上一交易日增加16.31%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163328a6a4566e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163328a6a4566e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","LU2328871848.SGD","LU2097828474.EUR","LU0455707207.USD","HK0000165453.HKD","LU2097828805.USD","LU2097828714.EUR","BK1589","LU2242644610.SGD","BK1161","LU1969619763.USD","LU2488822045.USD","BK1583","LU0502904849.HKD","01801","LU2097828631.EUR"],"gpt_icon":0},{"id":"2591619726","title":"信达生物12月15日主力净流出3053.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2591619726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591619726?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786539,"startTime":"0","endTime":"0","summary":"12月15日, 信达生物股价跌4.05%，报收81.75元，成交金额12.7亿元，换手率0.90%，振幅4.93%，量比0.76。信达生物今日主力资金净流出3053.2万元，上一交易日主力净流入2459.2万元。该股近5个交易日下跌3.97%，主力资金累计净流出1.5亿元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3.8亿元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161851a44d2e10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161851a44d2e10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828805.USD","LU2488822045.USD","BK1161","LU0455707207.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828474.EUR","LU2097828714.EUR","01801","HK0000165453.HKD","LU2242644610.SGD","LU2097828557.USD","BK1589","LU1969619763.USD","BK1583","LU0502904849.HKD"],"gpt_icon":0},{"id":"2591015695","title":"千亿市值创新药企俱乐部扩容！百济神州、百利天恒、信达生物等强势崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2591015695","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591015695?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:51","pubTimestamp":1765763499,"startTime":"0","endTime":"0","summary":"根据数据统计，截至11月19日，A股和港股的千亿市值创新药企俱乐部已扩容至8家。其中，百济神州A股总市值超过4000亿元，百利天恒总市值超过1500亿元。港股千亿市值俱乐部包括百济神州、翰森制药、信达生物、康方生物等。其中，总市值超4000亿元的创新药企业百济神州已连续两个季度实现盈利。据悉，在研发方面，百济神州的研发管线也进入集中兑现阶段，未来18个月将迎来20项关键里程碑事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","LU0588546209.SGD","06978","BK1589","LU2242644610.SGD","LU0307460666.USD","LU1251922891.USD","BK1583","LU2097828474.EUR","03692","91194","LU1770034418.SGD","01801","LU2097828631.EUR","BK1574","BK1588","LU2097828714.EUR","BK1161","LU2097828557.USD","LU1719994722.HKD","LU2097828805.USD","LU0455707207.USD","LU0502904849.HKD","HK0000165453.HKD","LU2488822045.USD","06160","BK1500","LU2328871848.SGD","02615","LU1969619763.USD"],"gpt_icon":0},{"id":"2591660538","title":"国产创新药迎利好密集期！九安医疗产品获FDA批准，一品红斩获近70亿元大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2591660538","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591660538?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:27","pubTimestamp":1765754852,"startTime":"0","endTime":"0","summary":"九安医疗公告，公司美国子公司四联检、三联检产品获得美国FDA上市前通知，涉及的产品包括甲型流感、乙型流感、COVID-19及RSV呼吸道合胞病毒四联检测家用试剂盒等。一品红公告，芩香清解口服液获批国家中药二级保护品种。这些优势使中国药企在全球医药交易中的占比迅速提升，2025年成为中国创新药对外授权交易的爆发之年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215073159a44b653b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215073159a44b653b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","HK0000165453.HKD","LU2328871848.SGD","01276","LU2097828474.EUR","LU2097828557.USD","LU2097828805.USD","01801","01877","03692","LU2242644610.SGD","LU2097828714.EUR","LU0502904849.HKD","LU1969619763.USD","LU2488822045.USD","BK1161","LU0455707207.USD","BK1589","LU2097828631.EUR","06978","BK1583"],"gpt_icon":0},{"id":"2591265911","title":"信达生物参与中整协体重与形体管理分会成立，倡导科学减重与健康形体新理念","url":"https://stock-news.laohu8.com/highlight/detail?id=2591265911","media":"信达生物","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591265911?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:02","pubTimestamp":1765670565,"startTime":"0","endTime":"0","summary":"大会期间，中国整形美容协会体重与形体管理分会正式成立，标志着我国医美健康产业在该细分领域迈向系统化与规范化。中国整形美容协会体重与形体管理分会成立仪式引领科学信达生物担任常任理事单位，共促行业规范发展体重管理与形体健康正成为医学与美学结合的重要方向。12月6日，由中整协体重与形体管理分会发起，信达生物参与支持的骑行活动于海口江东大道海滨开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214080943a69f8589&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214080943a69f8589&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU1969619763.USD","LU2097828714.EUR","01801","LU0502904849.HKD","HK0000165453.HKD","LU2097828474.EUR","LU2328871848.SGD","LU0455707207.USD","LU2097828805.USD","LU2242644610.SGD","LU2488822045.USD","BK1161","LU2097828557.USD","BK1589","LU2097828631.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0229},{"period":"1month","weight":-0.0714},{"period":"3month","weight":-0.0956},{"period":"6month","weight":0.0714},{"period":"1year","weight":1.3125},{"period":"ytd","weight":1.2746}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.056031},{"month":2,"riseRate":0.714286,"avgChangeRate":0.11927},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.021767},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.033324}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}